AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 187 filers reported holding AGIOS PHARMACEUTICALS INC in Q1 2024. The put-call ratio across all filers is 1.25 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2024 | $1,044,862 | +68.2% | 35,734 | +28.1% | 0.01% | +40.0% |
Q4 2023 | $621,288 | +183170.8% | 27,898 | +89.1% | 0.01% | 0.0% |
Q1 2023 | $339 | -52.8% | 14,755 | -42.3% | 0.01% | -64.3% |
Q4 2022 | $718 | -99.9% | 25,565 | +14.4% | 0.01% | 0.0% |
Q3 2022 | $632,000 | +25.4% | 22,344 | -1.7% | 0.01% | +7.7% |
Q2 2022 | $504,000 | -78.2% | 22,728 | -71.4% | 0.01% | -75.9% |
Q1 2022 | $2,309,000 | -16.2% | 79,335 | -5.3% | 0.05% | +17.4% |
Q4 2021 | $2,755,000 | +594.0% | 83,815 | +989.9% | 0.05% | +475.0% |
Q1 2021 | $397,000 | -63.3% | 7,690 | -69.2% | 0.01% | -74.2% |
Q4 2020 | $1,082,000 | -45.1% | 24,967 | -55.7% | 0.03% | -64.0% |
Q3 2020 | $1,972,000 | +118.9% | 56,338 | +234.4% | 0.09% | +91.1% |
Q2 2020 | $901,000 | +101.1% | 16,845 | +21.9% | 0.04% | +200.0% |
Q3 2019 | $448,000 | -2.0% | 13,815 | +50.8% | 0.02% | +15.4% |
Q2 2019 | $457,000 | +116.6% | 9,161 | +382.2% | 0.01% | +116.7% |
Q2 2015 | $211,000 | -8.7% | 1,900 | -7.8% | 0.01% | -25.0% |
Q4 2014 | $231,000 | – | 2,061 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Caligan Partners LP | 514,711 | $22,194,338 | 5.19% |
ACUTA CAPITAL PARTNERS, LLC | 78,700 | $3,393,544 | 2.86% |
Bellevue Group AG | 3,879,548 | $167,286,110 | 2.72% |
Parkman Healthcare Partners LLC | 446,416 | $19,249,458 | 2.58% |
Eagle Health Investments LP | 330,830 | $14,265,390 | 2.50% |
SECTOR GAMMA AS | 121,844 | $5,253,913 | 1.96% |
Frazier Life Sciences Management, L.P. | 871,974 | $37,599,519 | 1.76% |
BVF INC/IL | 1,190,107 | $51,317,414 | 1.44% |
Rock Springs Capital Management LP | 1,044,261 | $45,028,534 | 1.36% |
FARALLON CAPITAL MANAGEMENT LLC | 5,654,502 | $243,822,126 | 1.15% |